published meta-analysis   sensitivity analysis   studies

janus kinase (JAK) inhibitor in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] COV-BARRIER, 2021 0.57 [0.41; 0.79] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] 0.57[0.45; 0.73]ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, STOP-COVID (Guimarães), 202160%2,973lownot evaluable deathsdetailed resultsACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] COV-BARRIER, 2021 0.57 [0.41; 0.79] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62] 0.57[0.45; 0.73]ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, STOP-COVID (Guimarães), 202160%2,973lownot evaluable deaths (time to event analysis only)detailed resultsACTT-2 (Kalil), 2020 0.65 [0.39; 1.09] COV-BARRIER, 2021 0.57 [0.41; 0.79] 0.59[0.45; 0.78]ACTT-2 (Kalil), 2020, COV-BARRIER, 202120%2,558lownot evaluable clinical deteriorationdetailed resultsCOV-BARRIER, 2021 1.12 [0.58; 2.16] STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07] 0.78[0.38; 1.60]COV-BARRIER, 2021, STOP-COVID (Guimarães), 2021256%1,525lownot evaluable clinical improvementdetailed resultsACTT-2 (Kalil), 2020 1.16 [1.01; 1.33] COV-BARRIER, 2021 1.25 [1.04; 1.50] COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.22[1.07; 1.39]ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021510%2,684lowserious clinical improvement (14-day)detailed resultsACTT-2 (Kalil), 2020 1.30 [1.03; 1.64] COV-BARRIER, 2021 1.28 [1.05; 1.56] COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09] 1.31[1.13; 1.52]ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 202230%2,659lownot evaluable clinical improvement (28-day)detailed resultsCOV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.92[0.96; 3.82]COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202130%126lownot evaluable clinical improvement (time to event analysis only)detailed resultsACTT-2 (Kalil), 2020 1.16 [1.01; 1.33] 1.16[1.01; 1.33]ACTT-2 (Kalil), 202010%1,033NAnot evaluable death or ventilationdetailed resultsACTT-2 (Kalil), 2020 0.69 [0.50; 0.95] STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97] 0.67[0.52; 0.86]ACTT-2 (Kalil), 2020, STOP-COVID (Guimarães), 202120%1,322lownot evaluable mechanical ventilationdetailed resultsACTT-2 (Kalil), 2020 0.64 [0.44; 0.93] Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48] Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07] 0.37[0.09; 1.41]ACTT-2 (Kalil), 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021330%1,058lownot evaluable recoverydetailed resultsCOV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20] 1.57[0.77; 3.20]COV-BARRIER (critically ill), 202210%101NAnot evaluable related AE (TRAE)detailed resultsSingh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93] 1.26[0.14; 11.07]Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202120%25moderatenot evaluable superinfectiondetailed resultsACTT-2 (Kalil), 2020 0.50 [0.32; 0.79] 0.50[0.32; 0.79]ACTT-2 (Kalil), 202010%1,033NAnot evaluable adverse eventsdetailed resultsSingh (TD-0903 1mg), 2021 0.45 [0.01; 16.71] Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01] 0.12[0.01; 1.37]Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202122%25moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-10-31 23:53 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 1046,727,818,606,954,964,962,963,1045 - roots T: 290